Previous 10 | Next 10 |
2023-11-02 08:03:26 ET More on Geron Geron Corporation Stock: Another Buying Opportunity Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs FDA's Twist In Geron's Telomerase Tale (Rating Downgrade) Geron Q3 2023 Earnings Preview ...
Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Planning is ongoing for a potential commercial launch in the U.S. in mid-2024 Geron Corporation (Nasdaq: GERN), a late-stage...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Geron Corporation (GERN) is expected to report $-0.1 for Q3 2023
2023-11-01 13:01:15 ET More on Geron Geron Corporation Stock: Another Buying Opportunity Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs FDA's Twist In Geron's Telomerase Tale (Rating Downgrade) Geron blood cancer therapy accepted for...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its third quarter 2023 financial results and business highlights before the market opens on Thursday, November 2, 2023 via press release, which will be available on the Company&...
2023-10-23 15:30:59 ET Summary Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetelstat has a PDUFA on June 16, 2024, with an advisory committee meeting expected before that date. ...
2023-09-29 13:31:38 ET More on Geron Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs FDA's Twist In Geron's Telomerase Tale (Rating Downgrade) Geron Corporation (GERN) Q2 2023 Earnings Call Transcript Geron rises as Goldman Sachs upgr...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of trans...
2023-09-12 17:31:30 ET Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs analyst. Geron shares could shoot up to $4.0 Jenkins upgraded the biotech stock to “buy” on...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...